Orlistat (Synonyms: Ro 18-0647/002, (-)-Tetrahydrolipstatin) |
| Catalog No.GC17318 |
Orlistat is an irreversible inhibitor of lipases in the pancreas and stomach.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 96829-58-2
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Orlistat is an irreversible inhibitor of lipases in the pancreas and stomach. It is a drug for the treatment of obesity. It suppresses the action of gastrointestinal lipases, thereby impairing the metabolism of lipids in the gastrointestinal lumen, which can prevent the absorption of 30% of the lipids in dietary fat[1,2]. Orlistat is very hydrophobic and binds covalently to the active serine residues of pancreatic lipase. Orlistat passes through cell membranes sufficiently and exerts intracellular effects[3].
Orlistat(0-25µM;32h) induced a pronounced antiproliferative effect in the PC-3 cell line[4]. Orlistat inhibits Jurkat cell growth and induces a perturbation of cell cycle along with a decline of FASN activity and protein levels[6]. Orlistat-mediated(0-50µM) FASN inhibition could overcome sorafenib resistance and enhance cell killing in HCC by changing cell metabolism[7].
Orlistat(10 mg/kg/day, p.o.) alleviates colon cancer promotion in WD-driven CAC mice by suppressing inflammation, especially by inhibiting STAT3 and NF-κB activation[5].Orlistat(240 mg/kg/day;3 weeks; i.p.) prevented the growth of PC-3 tumors. Animals exhibited no outward signs of toxicity, experienced no loss of weight, nor were there any effects of Orlistat on hematocrit or WBC levels[4].
References:
[1]. Chandra P, Enespa, et,al. Microbial lipases and their industrial applications: a comprehensive review. Microb Cell Fact. 2020 Aug 26;19(1):169. doi: 10.1186/s12934-020-01428-8. PMID: 32847584; PMCID: PMC7449042.
[2]. Bansal AB, Al Khalili Y. Orlistat. 2022 Nov 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 31194359.
[3]. Padwal, et,al. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007, 369, 71-77.
[4]. Kridel SJ, Axelrod F, et,al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 Mar 15;64(6):2070-5. doi: 10.1158/0008-5472.can-03-3645. PMID: 15026345.
[5]. Jin BR, Kim HJ, et,al. Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling. Cells. 2021 Aug 11;10(8):2060. doi: 10.3390/cells10082060. PMID: 34440829; PMCID: PMC8394553.
[6]. Cioccoloni G, Aquino A, et,al. Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line. J Chemother. 2020 Feb;32(1):30-40. doi: 10.1080/1120009X.2019.1694761. Epub 2019 Nov 28. PMID: 31775585.
[7]. Shueng PW, Chan HW, et,al. Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism. Int J Mol Sci. 2022 Jun 10;23(12):6501. doi: 10.3390/ijms23126501. PMID: 35742944; PMCID: PMC9223797.
| Cell experiment [1]: | |
|
Cell lines |
prostate cancer cells(PC3) |
|
Preparation Method |
The effect of Orlistat on proliferation of prostate cancer cells was measured by the incorporation of bromodeoxyuridine (BrdUrd). PC-3 was seeded as subconfluent monolayers into microtiter plates. Cells were exposed to Orlistat for 32 h, then a BrdUrd labeling solution was added to the wells. |
|
Reaction Conditions |
0-25µM;32h |
|
Applications |
Orlistat induced a pronounced antiproliferative effect in the PC-3 cell line. |
| Animal experiment [2]: | |
|
Animal models |
Male athymic nude mice 4-5 weeks of age |
|
Preparation Method |
PC-3 cells were injected into the flank of nude mice. Tumors were allowed to grow until they reached a size of 100 mm3, at which time administration of Orlistat or vehicle was initiated in separate sets of 8 mice. Orlistat was administered at 240 mg/kg/day for a period of 3 weeks. |
|
Dosage form |
240 mg/kg/day;3 weeks; i.p. |
|
Applications |
Orlistat prevented the growth of PC-3 tumors. |
|
References: [1]. Kridel SJ, Axelrod F, et,al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 Mar 15;64(6):2070-5. doi: 10.1158/0008-5472.can-03-3645. PMID: 15026345. | |
| Cas No. | 96829-58-2 | SDF | |
| Synonyms | Ro 18-0647/002, (-)-Tetrahydrolipstatin | ||
| Chemical Name | [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate | ||
| Canonical SMILES | CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O | ||
| Formula | C29H53NO5 | M.Wt | 495.73 |
| Solubility | ≥ 17.4mg/mL in DMSO | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0172 mL | 10.0861 mL | 20.1723 mL |
| 5 mM | 0.4034 mL | 2.0172 mL | 4.0345 mL |
| 10 mM | 0.2017 mL | 1.0086 mL | 2.0172 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *